EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation

Bara M Hammadeh, Sadeen Sameer, Mohammed Alnajjar, Issam Abu-Issa, Mohammed S Alhallaq, Mustafa Ghazi, Ahmed Badr, Mays Shawawrah

Neurological Sciences · 2026-08 · 47 (8)

DOI: 10.1007/s10072-026-09211-0 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurological Sciences, online erschienen am 03.07.2026. Verfasst von Bara M Hammadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Al-Balqa' Applied University, Salt, Jordan. Barahammadeh2005@gmail.com. Hauptthemen laut MEDLINE: Immunologic Factors, Multiple Sclerosis, Relapsing-Remitting, Natalizumab. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Natalizumab is effective for relapsing-remitting multiple sclerosis (RRMS) but increases the risk of progressive multifocal leukoencephalopathy (PML). Extended-interval dosing (EID) may lessen this risk by reducing drug exposure, though its efficacy and safety compared with standard-interval dosing (SID) remain unclear. This review and meta-analysis evaluates both regimens across clinical and MRI outcomes. METHODS: Following PRISMA guidelines, we systematically searched PubMed, Scopus, Web of Science, Cochrane Library, and ScienceDirect from inception to July 2025. Eligible studies compared extended- (5-12 weeks) and standard-interval (4 weeks) natalizumab dosing in MS. Meta-analyses used random- or fixed-effects models with results as RR or MD based on heterogeneity (I²). RESULTS: Twenty-five studies were included. Analysis showed no significant differences between EID and SID in disability progression (MD -0.09, 95% CI: -0.46 to 0.29), or the risk of new T2 lesions (RR 1.24, 95% CI: 0.96 to 1.61). For PML incidence (RR 1.03, 95% CI: 0.29-3.60), the analysis was severely underpowered due to rare events; the wide confidence interval precludes any firm conclusion about comparative safety. However, EID was associated with a significantly higher risk of gadolinium-enhancing lesions (RR 1.35, 95% CI: 1.03-1.77). EID was associated with a borderline reduction in the risk of clinical relapse (RR 0.91, 95% CI: 0.83 to 1.00), but this finding is likely influenced by selection bias and should be considered hypothesis-generating rather than confirmatory. Subgroup analysis suggested a possible difference between intervals (P = 0.0323 for T2 lesions), but this finding is based on very sparse data, with only one subgroup (Q5-8 W) containing multiple studies and all other subgroups relying on single studies. Therefore, no definitive conclusion about optimal interval length can be drawn; the result is hypothesis-generating only. CONCLUSION: Extended-interval dosing of natalizumab shows efficacy and safety comparable to standard dosing. Although relapse reduction was noted, this may reflect selection bias. Shorter EID intervals (5-8 weeks) appear to maintain better radiologic control, supporting EID up to 6-8 weeks as a viable option pending long-term and biomarker-guided validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic FactorsMultiple Sclerosis, Relapsing-RemittingNatalizumabHumansTreatment OutcomeLeukoencephalopathy, Progressive Multifocal

Stichwörter der Autor:innen

EDSSExtended interval dosingMultiple sclerosisNatalizumabPML

Substanzen

Immunologic FactorsNatalizumab

Autor:innen und Institutionen

  • Al-Balqa' Applied University, Salt, Jordan. Barahammadeh2005@gmail.com.
  • Jordan University of Science and Technology, Irbid, Jordan.
  • Mansoura University, Mansoura, Egypt.
  • Department of General Surgery, Hamad Medical Corporation, Doha, Qatar.
  • Neurology Division, Department of Medicine, Queen's University, Kingston, ON, Canada.

Zitieren

APA

Hammadeh, B. M., Sameer, S., Alnajjar, M., Abu-Issa, I., Alhallaq, M. S., Ghazi, M., Badr, A., & Shawawrah, M. (2026). Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation. Neurological Sciences, 47(8). https://doi.org/10.1007/s10072-026-09211-0

Vancouver

Hammadeh BM, Sameer S, Alnajjar M, Abu-Issa I, Alhallaq MS, Ghazi M, et al. Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation. Neurological Sciences. 2026;47(8). doi:10.1007/s10072-026-09211-0

BibTeX
@article{Hammadeh2026,
  author = {Hammadeh, Bara M and Sameer, Sadeen and Alnajjar, Mohammed and Abu-Issa, Issam and Alhallaq, Mohammed S and Ghazi, Mustafa and Badr, Ahmed and Shawawrah, Mays},
  title = {Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation},
  journal = {Neurological Sciences},
  year = {2026},
  volume = {47},
  number = {8},
  doi = {10.1007/s10072-026-09211-0}
}
Kostenlos starten →